The use of biologicals in paediatric onset inflammatory bowel disease. Issue 10 (October 2016)

• Record Type: Journal Article
• Authors: Devadason, D.; Jones, K.; Rodrigues, A.
• Is Part Of: Paediatrics and child health. Volume 26:Issue 10(2016)
• Page Start: 441
• Page End: 444
• Publication Date: 2016-10
• Subjects: biologics -- biosimilars -- Crohn's disease -- inflammatory bowel disease -- steroid-sparing -- ulcerative colitis; Pediatrics -- Periodicals; Pediatrics -- Periodicals; Pédiatrie -- Périodiques; 618.920005
• DOI: 10.1016/j.paed.2016.07.004
• Languages: English
• ISSNs: 1751-7222

Abstract

Abstract: The treatment of inflammatory bowel disease (IBD) in childhood has undergone a quiet revolution over the last 15 years as newer agents, biologics, have been developed and then studied in children. These have, in combination with other immunomodulatory agents, transformed the care of children with inflammatory bowel disease. Importantly, they have very significantly decreased the reliance upon steroid-based therapies with their predictable undesirable effects upon growth and development. However, biologics are costly and have the potential for serious toxicity and longer term risks including that of malignancy. This article recounts the clinical experience with the available biological therapies, discusses the known risks and aims to offer the reader an overview of their utility in the management of paediatric IBD.